Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab


Tonyali O., Coskun U., Yuksel S., İNANÇ M., Bal O., Akman T., ...Daha Fazla

BREAST, cilt.25, ss.22-26, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.breast.2015.11.006
  • Dergi Adı: BREAST
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.22-26
  • Anahtar Kelimeler: Breast cancer, Adjuvant therapy, Trastuzumab, Brain metastasis, CENTRAL-NERVOUS-SYSTEM, RANDOMIZED-TRIALS, RECEPTOR STATUS, SURVIVAL, METAANALYSIS, CHEMOTHERAPY, SUBTYPES, THERAPY, NETWORK
  • Gazi Üniversitesi Adresli: Evet

Özet

Purpose: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab.